Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 20,866 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Non-treatment Clear all
Completed Phase 4 Interventional Results available

Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry

NCT01999946
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Extended-Release Naltrexone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Not applicable Interventional Results available

Integrated CBT-I and PE on Sleep and PTSD Outcomes (Impact Study)

NCT02774642
View directory record Official record
Conditions
Posttraumatic Stress Disorders, Chronic Insomnia
Interventions
CBTI-PE, Hygiene-PE
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
19 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Low-level Laser and Lifestyle Modifications

NCT05083442
View directory record Official record
Conditions
Overweight and Obesity, Weight Loss
Interventions
Low Level Laser Therapy, Sham (placebo)
Device · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 17, 2026, 8:20 AM EDT
Terminated Phase 4 Interventional

Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression

NCT00296686
View directory record Official record
Conditions
Major Depression
Interventions
Tranylcypromine, Dextroamphetamine, Triiodothyronine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Not applicable Interventional

ACT-ICU Study: Activity and Cognitive Therapy in the Intensive Care Unit

NCT01270269
View directory record Official record
Conditions
Brain Injuries, Dementia, Myopathies, Muscle Disorders
Interventions
Behavioral: Physical and functional rehabilitation, Behavioral: Cognitive, physical, & functional rehabilitation
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 17, 2026, 8:20 AM EDT
Recruiting No phase listed Observational

Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise

NCT03775954
View directory record Official record
Conditions
High Risk Pregnancy, Congenital Heart Disease, Fetal Hydrops, Twin Monochorionic Monoamniotic Placenta, Gastroschisis, Fetal Demise, Stillbirth, Fetal Arrhythmia, Long QT Syndrome, Intrauterine Fetal Death, Sudden Infant Death, Pregnancy Loss, Twin Twin Transfusion Syndrome, Birth Defect, Fetal Cardiac Anomaly, Fetal Cardiac Disorder, Fetal Death, Brugada Syndrome, Fetal Tachycardia
Interventions
Fetal Magnetocardiogram and Neonatal Electrocardiogram, Substudy only: Maternal/Infant Pharmacogenomic assessment postnatally
Diagnostic Test · Genetic
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Phase 4 Interventional Results available

Pectoralis and Serratus Muscle Blocks

NCT03743194
View directory record Official record
Conditions
Post Operative Pain Control
Interventions
Exparel 266 MG Per 20 ML Injection, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Not applicable Interventional Results available

Real World Expanded Multicenter Study of the MitraClip® System (REALISM)

NCT01931956
View directory record Official record
Conditions
Mitral Valve Insufficiency, Mitral Valve Regurgitation, Mitral Valve Incompetence, Mitral Regurgitation, Mitral Insufficiency
Interventions
MitraClip® implant
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
965 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
38
States / cities
Los Angeles, California • Mountain View, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients

NCT00018031
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
Peginterferon alfa-2b, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Not applicable Interventional Results available

Use of Neuromuscular Electrostimulation (NMES) for Treatment or Prevention of ICU-Associated Weakness

NCT00709124
View directory record Official record
Conditions
Intensive Care Unit, Muscle Weakness
Interventions
Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA), Sham
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Phase 1 Interventional

A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies

NCT02651662
View directory record Official record
Conditions
Relapsed/Refractory Aggressive B-Cell Lymphoma
Interventions
cemiplimab, odronextamab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Phase 1 Interventional

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

NCT05375903
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
Interventions
UGN-301, UGN-201, Gemcitabine
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Classroom Behavior Support (CBS) Project

NCT05137327
View directory record Official record
Conditions
ADHD
Interventions
Classroom Behavior Support (CBS) Condition, Standard Problem Solving Consultation
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
5 Years to 12 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 17, 2026, 8:20 AM EDT
Recruiting Not applicable Interventional

Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

NCT06943586
View directory record Official record
Conditions
Stroke, Transient Ischemic Attack (TIA)
Interventions
CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)
Genetic
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 17, 2026, 8:20 AM EDT
Terminated Not applicable Interventional

Efficacy of a Mechanical Chair for Treatment of Benign Paroxysmal Positional Vertigo (BPPV)

NCT03161470
View directory record Official record
Conditions
Vertigo, Benign Paroxysmal Positional Vertigo
Interventions
Standard Repositioning, Mechanical Chair Repositioning, Sham Treatment
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

Phase 2b Study in NASH to Assess IVA337

NCT03008070
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
IVA337, Placebo
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
14
States / cities
Madison, Alabama • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 17, 2026, 8:20 AM EDT
Withdrawn Phase 1 Interventional

Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection

NCT05867056
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
IMC-I109V Single Ascending Dose, IMC-I109V Multiple Ascending Doses, HBV HCC Module MAD
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Not applicable Interventional

Effectiveness of Acupuncture for Depressed Patients Not Taking Antidepressant Medications

NCT01634022
View directory record Official record
Conditions
Depression
Interventions
Acupuncture
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2012 · Synced Oct 17, 2026, 8:20 AM EDT
Terminated No phase listed Observational

Journey II BCS CMS Total Knee System Compared to Other PS Total Knee Systems in PT Setting

NCT02820766
View directory record Official record
Conditions
Osteoarthritis, Degenerative Arthritis, Traumatic Arthritis
Interventions
Not listed
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Annapolis, Maryland • Eugene, Oregon • State College, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection

NCT04639466
View directory record Official record
Conditions
COVID-19 Infection
Interventions
Placebo Administration, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Drug · Biological
Lead sponsor
GeoVax, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
3
States / cities
Claremont, California • Duarte, California • Thousand Oaks, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 17, 2026, 8:20 AM EDT
Completed No phase listed Observational

Pharmacogenomic Analysis in Pediatric Acute Lymphoblastic Leukemia

NCT04770922
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric, Adverse Drug Event
Interventions
Not listed
Lead sponsor
Cipherome, Inc.
Industry
Eligibility
Up to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 17, 2026, 8:20 AM EDT
Terminated Phase 1 Interventional Results available

Direct Peritoneal Resuscitation in Gastroschisis

NCT03205553
View directory record Official record
Conditions
Gastroschisis
Interventions
SoC Staged Silo Closure, Peritoneal Dialysis Solution/Dextrose 1.5%
Procedure · Drug
Lead sponsor
University of Arkansas
Other
Eligibility
0 Hours to 12 Hours
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 17, 2026, 8:20 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

NCT06559306
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 8:20 AM EDT
Completed Not applicable Interventional Results available

Effect of Modulating Gamma Oscillations Using tACS

NCT03412604
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Transcranial Alternating Current Stimulation (tACS)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 17, 2026, 8:20 AM EDT